In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
Getting NCI clinical trials to the community has never been an easy task. Has it been getting simpler or more difficult in recent years?
